SPIDIMAN (Single-Port Insulin Infusion for Improved Diabetes Management) started on November 1st, 2012. During the next 4 years it aims to improve glycaemic management for better quality of life and healthier aging by exploiting a novel glucose sensor technology. The consortium, consisting of well experienced participants, will develop an innovative artificial pancreas approach and perform clinical validation in a European network of specialized diabetes centres. SPIDIMAN will pave the way for a new single-port device which will advance diabetes management especially for patients in childhood and adolescence.
This project is funded by the EU Framework 7 Programme, contract no 305343.